On our mission to develop better medicines, we have secured some valuable collaborations
Our collaborations and partnerships include:
In December 2022, Nykode entered into a clinical supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate VB10.16 in combination with KEYTRUDA® (pembrolizumab) in patients with HPV16-positive head and neck cancer. Under the terms of the agreement, MSD will supply KEYTRUDA. Nykode retains all commercial rights to VB10.16 worldwide.
In November 2021, we entered into a multi-target agreement covering five vaccine research programs, three within cancer vaccines, and two within infectious disease vaccines.
In July 2021, we entered an agreement with Adaptive to exclusively license their validated SARS-CoV-2 T cell epitopes for use in our next-generation SARS-CoV-2 vaccine candidates.
In October 2020, we announced a global license and development agreement for VB10.NEO with Genenetch, Inc., a Roche company. Under the terms of the agreement, we granted Genenetech an exclusive worldwide license to develop and commercialize our individualized cancer vaccine, VB10.NEO.
In February 2019, we entered a collaboration with Roche to explore a combination of our cancer vaccine VB10. and Roche’s PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced cervical cancer. Nykode and Roche will each maintain ownership of their own compounds in the clinical collaboration. We are running the phase II trial, with up to 50 cervical cancer patients enrolled.
In September 2018, we announced a clinical collaboration with Nektar Therapeutics to evaluate the combination of VB10.NEO in combination with Nektar’s CD-122-biased agonist, NKTR-214, in patients with squamous cell carcinoma of the head and neck. Nykode Therapeutics and Nektar will each maintain ownership of their own compounds in the clinical collaboration. The trial is fully enrolled. Since October 2021, VB10.NEO is exclusively licensed to Genentech, Inc.